Add to ORKGOvercoming acquired resistance to cetuximab by dual targeting HER family receptors with Conclusions: These studies demonstrate that dually targeting HER family receptors with antibody-based therapies can Iida et al. Molecular Cancer 2014, 13:24
The EGFR monoclonal antibody cetuximab is the only approved targeted agent for treating head and nec...
Several targeted agents interfering with signaling effectors have been evaluated and have demonstrat...
HER2-positive breast cancer (HER2\u2009+\u2009BC) represents 15-20% of all BCs. In the last two deca...
Item does not contain fulltextCetuximab, an antibody against the EGFR, has shown efficacy in treatin...
Cetuximab, the FDA-approved anti-EGFR antibody for head and neck squamous cell carcinoma (HNSCC), ha...
Purpose: Our previous work suggested that HER3 inhibition sensitizes head and neck squamous cell car...
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety...
Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodie...
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squa...
The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in h...
The epidermal growth factor receptor (EGFR) is an important therapeutic target in colorectal cancer ...
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that was approved in 2013 to treat...
PURPOSE: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefi...
Abstract: Aim: Acquired resistance to the targeted agent cetuximab poses a significant challenge in ...
The treatment of HER2-positive metastatic breast cancer (mBC) with Trastuzumab emtansine (T-DM1) and...
The EGFR monoclonal antibody cetuximab is the only approved targeted agent for treating head and nec...
Several targeted agents interfering with signaling effectors have been evaluated and have demonstrat...
HER2-positive breast cancer (HER2\u2009+\u2009BC) represents 15-20% of all BCs. In the last two deca...
Item does not contain fulltextCetuximab, an antibody against the EGFR, has shown efficacy in treatin...
Cetuximab, the FDA-approved anti-EGFR antibody for head and neck squamous cell carcinoma (HNSCC), ha...
Purpose: Our previous work suggested that HER3 inhibition sensitizes head and neck squamous cell car...
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety...
Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodie...
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squa...
The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in h...
The epidermal growth factor receptor (EGFR) is an important therapeutic target in colorectal cancer ...
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that was approved in 2013 to treat...
PURPOSE: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefi...
Abstract: Aim: Acquired resistance to the targeted agent cetuximab poses a significant challenge in ...
The treatment of HER2-positive metastatic breast cancer (mBC) with Trastuzumab emtansine (T-DM1) and...
The EGFR monoclonal antibody cetuximab is the only approved targeted agent for treating head and nec...
Several targeted agents interfering with signaling effectors have been evaluated and have demonstrat...
HER2-positive breast cancer (HER2\u2009+\u2009BC) represents 15-20% of all BCs. In the last two deca...